vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Rollins, Inc. (ROL). Click either name above to swap in a different company.

Rollins, Inc. is the larger business by last-quarter revenue ($906.4M vs $487.7M, roughly 1.9× CLOVER HEALTH INVESTMENTS, CORP.). Rollins, Inc. runs the higher net margin — 11.9% vs -10.1%, a 22.0% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 10.2%). Rollins, Inc. produced more free cash flow last quarter ($111.2M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 0.8%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Rollins, Inc. is a North American pest control company serving residential and commercial clients. Operating globally through its wholly owned subsidiaries, Orkin, Inc., PCO Services, HomeTeam Pest Defense, Western Pest Services, Industrial Fumigant Company, TruTech, Critter Control, Crane, Waltham, OPC Services, PermaTreat, Northwest Exterminating, McCall Service and Clark Pest Control, as well UK subsidiaries Integrated Pest Management Limited, Safeguard Pest Control, NBC Environment, Europ...

CLOV vs ROL — Head-to-Head

Bigger by revenue
ROL
ROL
1.9× larger
ROL
$906.4M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+34.5% gap
CLOV
44.7%
10.2%
ROL
Higher net margin
ROL
ROL
22.0% more per $
ROL
11.9%
-10.1%
CLOV
More free cash flow
ROL
ROL
$180.2M more FCF
ROL
$111.2M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
0.8%
ROL

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CLOV
CLOV
ROL
ROL
Revenue
$487.7M
$906.4M
Net Profit
$-49.3M
$107.8M
Gross Margin
Operating Margin
-10.1%
16.1%
Net Margin
-10.1%
11.9%
Revenue YoY
44.7%
10.2%
Net Profit YoY
-123.2%
2.5%
EPS (diluted)
$0.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
ROL
ROL
Q1 26
$906.4M
Q4 25
$487.7M
$912.9M
Q3 25
$496.6M
$1.0B
Q2 25
$477.6M
$999.5M
Q1 25
$462.3M
$822.5M
Q4 24
$337.0M
$832.2M
Q3 24
$331.0M
$916.3M
Q2 24
$356.3M
$891.9M
Net Profit
CLOV
CLOV
ROL
ROL
Q1 26
$107.8M
Q4 25
$-49.3M
$116.4M
Q3 25
$-24.4M
$163.5M
Q2 25
$-10.6M
$141.5M
Q1 25
$-1.3M
$105.2M
Q4 24
$-22.1M
$105.7M
Q3 24
$-9.2M
$136.9M
Q2 24
$7.4M
$129.4M
Gross Margin
CLOV
CLOV
ROL
ROL
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
24.5%
Q2 24
30.3%
Operating Margin
CLOV
CLOV
ROL
ROL
Q1 26
16.1%
Q4 25
-10.1%
17.5%
Q3 25
-4.9%
21.9%
Q2 25
-2.2%
19.8%
Q1 25
-0.3%
17.3%
Q4 24
-6.4%
18.1%
Q3 24
-2.7%
20.9%
Q2 24
2.0%
20.4%
Net Margin
CLOV
CLOV
ROL
ROL
Q1 26
11.9%
Q4 25
-10.1%
12.8%
Q3 25
-4.9%
15.9%
Q2 25
-2.2%
14.2%
Q1 25
-0.3%
12.8%
Q4 24
-6.6%
12.7%
Q3 24
-2.8%
14.9%
Q2 24
2.1%
14.5%
EPS (diluted)
CLOV
CLOV
ROL
ROL
Q1 26
$0.22
Q4 25
$0.24
Q3 25
$0.34
Q2 25
$0.29
Q1 25
$0.22
Q4 24
$0.22
Q3 24
$0.28
Q2 24
$0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
ROL
ROL
Cash + ST InvestmentsLiquidity on hand
$78.3M
$116.5M
Total DebtLower is stronger
$650.6M
Stockholders' EquityBook value
$308.7M
$1.4B
Total Assets
$541.0M
$3.2B
Debt / EquityLower = less leverage
0.47×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
ROL
ROL
Q1 26
$116.5M
Q4 25
$78.3M
$100.0M
Q3 25
$127.4M
Q2 25
$123.0M
Q1 25
$201.2M
Q4 24
$194.5M
$89.6M
Q3 24
$288.0M
$95.3M
Q2 24
$254.8M
$106.7M
Total Debt
CLOV
CLOV
ROL
ROL
Q1 26
$650.6M
Q4 25
$486.1M
Q3 25
$485.7M
Q2 25
$485.3M
Q1 25
$485.5M
Q4 24
$395.3M
Q3 24
Q2 24
Stockholders' Equity
CLOV
CLOV
ROL
ROL
Q1 26
$1.4B
Q4 25
$308.7M
$1.4B
Q3 25
$340.9M
$1.5B
Q2 25
$344.2M
$1.4B
Q1 25
$336.1M
$1.4B
Q4 24
$341.1M
$1.3B
Q3 24
$342.2M
$1.3B
Q2 24
$324.9M
$1.2B
Total Assets
CLOV
CLOV
ROL
ROL
Q1 26
$3.2B
Q4 25
$541.0M
$3.1B
Q3 25
$559.7M
$3.2B
Q2 25
$575.0M
$3.2B
Q1 25
$583.7M
$2.9B
Q4 24
$580.7M
$2.8B
Q3 24
$653.0M
$2.8B
Q2 24
$674.2M
$2.8B
Debt / Equity
CLOV
CLOV
ROL
ROL
Q1 26
0.47×
Q4 25
0.35×
Q3 25
0.32×
Q2 25
0.34×
Q1 25
0.36×
Q4 24
0.30×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
ROL
ROL
Operating Cash FlowLast quarter
$-66.9M
$118.4M
Free Cash FlowOCF − Capex
$-69.0M
$111.2M
FCF MarginFCF / Revenue
-14.1%
12.3%
Capex IntensityCapex / Revenue
0.4%
0.8%
Cash ConversionOCF / Net Profit
1.10×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$621.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
ROL
ROL
Q1 26
$118.4M
Q4 25
$-66.9M
$164.7M
Q3 25
$12.1M
$191.3M
Q2 25
$5.4M
$175.1M
Q1 25
$-16.3M
$146.9M
Q4 24
$34.8M
$188.2M
Q3 24
$50.0M
$146.9M
Q2 24
$44.8M
$145.1M
Free Cash Flow
CLOV
CLOV
ROL
ROL
Q1 26
$111.2M
Q4 25
$-69.0M
$159.0M
Q3 25
$11.4M
$182.8M
Q2 25
$4.8M
$168.0M
Q1 25
$-16.5M
$140.1M
Q4 24
$33.3M
$184.0M
Q3 24
$49.6M
$139.4M
Q2 24
$44.4M
$136.4M
FCF Margin
CLOV
CLOV
ROL
ROL
Q1 26
12.3%
Q4 25
-14.1%
17.4%
Q3 25
2.3%
17.8%
Q2 25
1.0%
16.8%
Q1 25
-3.6%
17.0%
Q4 24
9.9%
22.1%
Q3 24
15.0%
15.2%
Q2 24
12.5%
15.3%
Capex Intensity
CLOV
CLOV
ROL
ROL
Q1 26
0.8%
Q4 25
0.4%
0.6%
Q3 25
0.1%
0.8%
Q2 25
0.1%
0.7%
Q1 25
0.0%
0.8%
Q4 24
0.5%
0.5%
Q3 24
0.1%
0.8%
Q2 24
0.1%
1.0%
Cash Conversion
CLOV
CLOV
ROL
ROL
Q1 26
1.10×
Q4 25
1.41×
Q3 25
1.17×
Q2 25
1.24×
Q1 25
1.40×
Q4 24
1.78×
Q3 24
1.07×
Q2 24
6.04×
1.12×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons